Antipsychotic-induced extrapyramidal syndromes

  title={Antipsychotic-induced extrapyramidal syndromes},
  author={Igor Schillevoort and Anthonius de Boer and Ron M. C. Herings and Raymund A. C. Roos and Paul Jansen and Hubert G. M. Leufkens},
  journal={European Journal of Clinical Pharmacology},
Abstract. Aim: To compare the risk of extrapyramidal syndromes (EPS) between patients using risperidone and those using low-potency conventional antipsychotic drugs (APDs) in outpatient clinical practice, as measured by the use of anticholinergic medication. We tried to replicate results from previous clinical trials that compared risperidone with high-potency APDs. Method: Data was obtained from the PHARMO database containing filled prescriptions of 450,000 community-dwelling people in The… 

Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics

Risperidone was associated with more EPS compared with other medications and a higher threshold for the “maximum dose” of paliperidone could be considered and higher doses used with the same cautions as low-average doses.

Severe parkinsonism under treatment with antipsychotic drugs

The first-generation low-potency APDs had significantly reduced risk of severe parkinsonism compared not only to high potency but also to second-generation APDs.

A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I.

Any attempt to develop personalized dosing needs to be anchored in the understanding of the pharmacological response of each drug in each person's environment, particularly drug-drug interactions (DDIs) and how genetic make-up influences drug response.

Association Between Antipsychotic Treatment and Neurological Adverse Events in Pediatric Patients: A Population-Based Cohort Study in Korea

It is suggested that antipsychotics should be used with caution in pediatric patients, especially regarding initial exposure, high dose, and polypharmacy of antipsychotic medication.

Haloperidol in palliative care: Indications and risks.

Personalized antipsychotic treatment: the adverse effects perspectives.

There are no practical pharmakogenetic tests that could be used in everyday clinical practice; however, in the field of psychiatry they are expected within a few years and will indubitably become an important tool for personalized prescription.

Are Second Generation Antipsychotics a Distinct Class?

Although data are very limited, mid- and low-potency first-generation antipsychotics show efficacy and extrapyramidal side effects that are comparable to those of second- Generation antipsychotic medication.

Cinnarizine- and flunarizine-associated movement disorder: a literature review

  • J. RissardoA. Caprara
  • Medicine, Psychology
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
  • 2020
Parkinsonism was the most well described MD and myoclonus was the poorest described MD with missing data about the neurological examination and electrodiagnostic studies.

The Personal Antipsychotic Choice Index.

An updateable tool to produce individual ranking of antipsychotics based on the patients' input is presented, which shows effectiveness concerning psychotic, depressive and cognitive symptoms, weight gain, sexual dysfunction, drowsiness and extrapyramidal symptoms.